A Risk Evaluation and Mitigation Strategy (REMS) is a specialized regulatory program mandated by the U.S. Food and Drug Administration (FDA) to manage known or potential serious risks associated with a medicine. Authorized under the Food and Drug Administration Amendments Act (FDAAA) of 2007, which added Section 505-1 to the Federal Food, Drug, and Cosmetic Act (codified at 21 U.S.C. § 355-1), a REMS is required when the FDA determines that standard labeling is insufficient to ensure that the benefits of a drug outweigh its risks.
For pharmaceutical developers, regulatory affairs professionals, specialty distributors, and market access leads, navigating REMS requirements is a critical milestone in both brand-name drug launches and generic/biosimilar development. Because REMS programs impose strict administrative and logistical controls on how a drug is prescribed, dispensed, and administered, they function as both a patient safety shield and a major operational bottleneck.
This guide details the elements of a REMS, analyzes the levels of Elements to Assure Safe Use (ETASU), evaluates the Single Shared REMS (SSRS) negotiation process in generic drug entry, outlines the FDA waiver pathways, and reviews the landmark 2025 termination of the clozapine REMS program.
REMS Elements and ETASU: From Medication Guides to Certified Healthcare Settings
A REMS program can consist of one or several elements, depending on the severity and nature of the safety risk (e.g., severe teratogenicity, neutropenia, cytokine release syndrome, or addiction). The FDA REMS Public Dashboard listed roughly 70 active REMS programs as of mid-2025, and over 90% of those active programs contain Elements to Assure Safe Use (ETASU) — the most restrictive category of requirements.
Low Complexity REMS:
Medication Guide + Communication Plan
(Simple patient leaflets & provider letters)
High Complexity REMS (ETASU under 21 U.S.C. § 355-1):
Prescriber Certification -> Pharmacy Certification -> Restricted Administration Setting -> Patient Registry
Basic REMS Components
Historically, REMS programs could include relatively low-intervention components:
- Medication Guides: Patient-facing handouts detailing specific risks. (Note: While Medication Guides were once a common stand-alone REMS element, the FDA has largely transitioned them to standard labeling, reserving REMS for more intensive programs).
- Communication Plans: FDA-approved materials distributed by the manufacturer to inform healthcare providers about the risks and REMS requirements. These include letters to professional societies, educational slide decks, and website portals.
Elements to Assure Safe Use (ETASU)
For high-risk drugs, the FDA mandates Elements to Assure Safe Use (ETASU) under 21 U.S.C. § 355-1(f)(3). ETASUs are the most restrictive components of a REMS and can include any combination of the following requirements:
- Prescriber Certification (ETASU A): Healthcare providers who prescribe the drug must undergo training, pass a knowledge assessment, and formally enroll in the REMS program.
- Pharmacy/Dispensing Certification (ETASU B): Pharmacies, hospitals, or infusion clinics that dispense the drug must be certified. This requires the facility to train staff, establish procedures to verify patient eligibility, and agree to audit protocols.
- Restricted Administration Settings (ETASU C): The drug may only be administered in certified healthcare settings, such as hospitals or specialized infusion centers.
- Patient Documentation and Monitoring (ETASU D & E): The drug may only be dispensed to patients with documentation of safe-use conditions. This often requires regular laboratory testing (e.g., liver function tests, pregnancy tests, or blood counts) and registering the patient in a central database.
- Patient Registries (ETASU F): The manufacturer must maintain a registry of all patients receiving the drug to track long-term safety outcomes and ensure compliance with monitoring schedules.
For a detailed analysis of how restricted settings and pharmacy certifications impact distribution logistics, pharmacy inventory lockouts, and patient hub triage, see REMS distribution and specialty pharmacy bottlenecks.
Under the Hood of High-Complexity ETASU: Spravato and Thalomid
To appreciate how high-complexity ETASU requirements function in daily practice, it is useful to examine two prominent models of strict REMS administration: Janssen’s Spravato (esketamine) and Celgene’s (Bristol Myers Squibb) Thalomid (thalidomide).
The SPRAVATO REMS Program: Direct-Observation ETASU
Spravato, approved for treatment-resistant depression and depressive symptoms in adults with acute suicidal ideation, is subject to a REMS designed to mitigate the risks of serious adverse outcomes resulting from sedation, dissociation, and abuse/misuse:
- Observation Mandate: Spravato is a nasal spray self-administered by the patient, but under the law, it must be administered under the direct supervision of a healthcare professional. The patient cannot take the drug home.
- Post-Dose Monitoring: The certified healthcare setting must monitor the patient for a minimum of two hours after drug administration to check for clinical resolution of sedation and blood pressure spikes.
- Payer Coding Integration: Because the drug must be administered in-office, the billing utilizes outpatient medical codes (such as G2082 or G2083 for office visits including esketamine administration) and is routed through the outpatient medical benefit. For a product-specific analysis of clinical coverage and coding pathways, see Spravato esketamine REMS access requirements.
The THALOMID REMS Program: Teratogenicity and Registry ETASU
Thalidomide, a treatment for multiple myeloma and erythema nodosum leprosum, is one of the most tightly controlled drugs in the United States due to its severe teratogenicity (risk of severe birth defects):
- Bimonthly Pregnancy Testing: Female patients of childbearing potential must undergo a negative pregnancy test within 24 hours prior to initiating therapy, weekly during the first 4 weeks, and then every 2 to 4 weeks depending on menstrual cycle regularity.
- Mandatory Patient Surveys: Before a pharmacy can dispense Thalomid, both the patient and the prescriber must complete a phone or online survey confirming compliance with contraceptive requirements.
- System Verification Codes (SVC): The pharmacy must obtain a confirmation number (SVC) from the Thalomid REMS database before dispensing. The drug quantity is strictly limited to a 28-day supply with no automatic refills allowed.
The Single Shared REMS (SSRS) Mandate: Generic Negotiation and Waiver Pathways
When a generic drug developer (under an Abbreviated New Drug Application, or ANDA) or a biosimilar developer (under a 351(k) biologics license application) seeks approval for a drug subject to an active ETASU REMS, federal law mandates that the brand manufacturer (reference listed drug, or RLD) and the generic applicant collaborate to implement a Single Shared REMS (SSRS).
The Shared REMS Generic Negotiation
The goal of the SSRS mandate is to create a single, unified program for both the brand and generic versions of the drug:
- Administrative Unity: Prescribers and pharmacies only have to enroll in one registry, use one portal, and follow one set of rules, regardless of whether they prescribe the brand or generic product.
- Cost Sharing: The brand and generic manufacturers share the operational costs of the REMS program (e.g., maintaining the registry database, call center, and audit teams) based on market share or pre-negotiated formulas.
However, the negotiation of an SSRS is a notorious flashpoint for anti-competitive behavior, colloquially referred to in the industry as the "Shared REMS Patent Dance":
- Delays: Brand manufacturers have a strong financial incentive to delay the launch of generic competitors. Because an SSRS requires joint agreement on technical architecture, legal liability, and cost sharing, brand firms can drag out negotiations for months or years.
- Access to Physical Product: Under 21 U.S.C. § 355-1(f)(8), brand manufacturers are prohibited from using REMS to block generic developers from obtaining physical samples of the drug needed for bioequivalence testing. Despite this, some brand firms refuse to sell samples to generic developers, citing REMS safety restrictions as a liability shield.
SSRS Litigation Case Studies
The legal stakes of SSRS negotiations are illustrated by high-profile antitrust disputes:
- Celgene (Revlimid/Thalomid) Antitrust Litigation: Generic manufacturers (including Mylan, Dr. Reddy's, and Natco) filed antitrust lawsuits alleging that Celgene utilized its restricted-distribution REMS programs to refuse to sell physical samples of Revlimid (lenalidomide) and Thalomid (thalidomide) for bioequivalence testing — the tactic widely dubbed "REMS-gate." The FDA responded with safety-determination letters clarifying that supplying samples would not violate the REMS, and Celgene ultimately entered into settlements to supply the necessary samples. For the product-specific Revlimid generic-entry timeline and how "REMS-gate" shaped its staggered launch, see the Revlimid generic market and REMS-gate analysis.
- Jazz Pharmaceuticals (Xyrem) Litigation: Generic developers of sodium oxybate accused Jazz of using the Xyrem REMS program as a monopoly maintenance tool. Jazz’s proprietary REMS portal served as a single-channel database, and generic developers argued that Jazz dragged out negotiations over database access to delay ANDA approvals. This dispute ultimately led to the FDA granting a REMS waiver to the generic applicants.
The CREATES Act of 2019: Resolving Sample Access Disputes
To dismantle these anti-competitive roadblocks, Congress enacted the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act in December 2019. The CREATES Act established a clear, fast-track pathway for generic developers to obtain samples:
- Private Right of Action: Generic and biosimilar developers are empowered to bring a civil action in federal district court against a brand manufacturer that refuses to provide sufficient quantities of the reference drug on "commercially reasonable, market-based terms."
- Judicial Relief: If the court finds that the brand manufacturer delayed sample access in bad faith, it can order the brand to provide the samples immediately, award attorney fees and litigation costs to the generic developer, and levy a significant financial penalty (up to the revenue the brand earned from the drug during the delay period) as a deterrent.
- Waiver Simplification: The Act also streamlined the FDA waiver process, encouraging the agency to grant waivers allowing generic applicants to develop their own comparable safety programs rather than forcing them to wait for the resolution of protracted shared REMS negotiations.
The FDA Waiver Pathway
To prevent brand manufacturers from using SSRS negotiations as an indefinite barrier to generic entry, Section 505-1(i)(1)(B) of the FD&C Act gives the FDA authority to grant a waiver of the single shared REMS requirement.
If the FDA grants a waiver:
- The generic applicant is permitted to launch its product with an independent REMS program rather than joining the brand's shared system.
- The independent generic REMS must achieve the same safety goals and utilize the same clinical criteria as the brand program, but it runs on its own administrative database and portal.
Standard Pathway:
Brand RLD + Generic ANDA ---> Single Shared REMS (SSRS) ---> Unified Portal & Shared Costs
Waiver Pathway (Negotiations Fail):
Brand RLD ---> RLD REMS Program (Independent Portal)
Generic ANDA ---> Generic-Specific REMS Program (Independent Portal)
The FDA routinely evaluates waiver requests when negotiations have stalled for more than a year. Historical examples include:
- Alosetron: The FDA granted a waiver allowing a generic developer to implement an independent REMS for alosetron (Lotronex) after negotiations for a shared program collapsed.
- Sodium Oxybate: The FDA granted a waiver to generic sodium oxybate (Xyrem) developers, permitting an independent REMS due to the brand's complex, proprietary distribution model.
The Economic Burden of REMS Compliance on Healthcare Providers
While the safety intent of REMS is clear, the administrative and financial cost of compliance is borne heavily by clinical practices, hospitals, and pharmacies.
Personnel and Administrative Time
Complying with high-complexity ETASU requirements requires significant staff resources:
- Staff Certification: Clinical offices must dedicate hours to training nurses, physicians, and administrative staff on the specific registry portals.
- Documentation Coordination: Coordinating weekly or monthly laboratory tests (e.g., ANC counts or pregnancy screens) and manually uploading results to the REMS portal takes clinical staff away from direct patient care.
- Audit Preparedness: Certified pharmacies and clinics must maintain extensive records of all dispenses and registry verifications, preparing for random audits by the drug manufacturer or the FDA.
Software and Integration Costs
For hospital systems and large pharmacy chains, managing multiple disconnected REMS portals is an operational nightmare. While some efforts have been made to integrate REMS requirements directly into Electronic Health Record (EHR) systems using pharmacy standards (such as the NCPDP SCRIPT standard), the majority of REMS programs still require users to log into proprietary external websites, increasing the risk of transcription errors and dispensing delays.
REMS as an Access Bottleneck: The Clozapine 2025 Termination and Distribution Lessons
While REMS programs are designed to protect patient safety, they impose significant administrative burdens on the healthcare system. The clinical coordination required to track laboratory results, verify pharmacy certifications, and submit authorizations can lead to treatment interruptions and delayed access.
A landmark case study in the evolution of REMS oversight is the Clozapine REMS program termination.
The Clozapine REMS Program: A Legacy of Burden
Clozapine is an atypical antipsychotic indicated for treatment-resistant schizophrenia. It is highly effective but carries a known risk of severe neutropenia (a dangerous drop in white blood cells that can lead to life-threatening infections).
To manage this risk, the FDA historically mandated a strict REMS program:
- Prescribers and pharmacies had to be certified.
- Patients had to undergo regular blood draws to monitor their Absolute Neutrophil Count (ANC).
- The pharmacy could not dispense clozapine without verifying the patient's ANC results in the central Clozapine REMS registry database, generating a "dispense authorization."
In late 2021, the FDA transitioned the clozapine program to a new, unified administrative platform. The transition was plagued by technical glitches:
- The registry website crashed, phone lines were overwhelmed, and pharmacies were unable to generate dispense authorizations.
- Thousands of patients with schizophrenia faced sudden, involuntary treatment interruptions.
- Because abrupt clozapine discontinuation can trigger severe psychotic relapse and withdrawal symptoms, the medical community, led by the American Psychiatric Association (APA) and pharmacy groups, petitioned the FDA to suspend or eliminate the program.
The February 24, 2025 Termination
Following a comprehensive review of the safety database, the November 19, 2024 joint meeting of the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee, and public feedback, the FDA announced that the Clozapine REMS requirements would cease effective February 24, 2025, and completed the formal regulatory removal of the REMS effective June 13, 2025.
Key outcomes of the clozapine REMS termination include:
- Removal of Certification Requirements: Prescribers and pharmacies are no longer required to be certified or enrolled in the Clozapine REMS program to prescribe or dispense the drug.
- Elimination of the Registry Lock: Pharmacies no longer need to submit ANC blood test results to a central database or secure a dispense authorization before handing the medication to a patient.
- Prescribing Guidelines and Boxed Warnings: While the administrative registry has been dismantled, the clinical risk remains. The FDA maintained the severe neutropenia Boxed Warning on the clozapine label. Clinicians are still required to monitor patients' ANC levels according to the frequency schedule outlined in the prescribing information, but this is now managed through standard clinical practice rather than a mandatory federal database.
The clozapine case demonstrates a growing regulatory recognition that when the administrative burden of a REMS begins to cause more clinical harm (via treatment gaps and administrative barriers) than the underlying safety risk it seeks to prevent, the program must be modified or retired.
Specialty Pharmacy Routing: Operational Coordination of REMS Drugs
Because of the strict certification and tracking requirements associated with ETASU programs, manufacturers rarely distribute REMS drugs through standard broad-market wholesale channels. Instead, they utilize limited distribution networks consisting of a small number of certified specialty pharmacies.
The Specialty Pharmacy Triage Workflow
When a certified provider writes a prescription for a REMS drug, the process follows a structured specialty pharmacy triage:
[Certified Provider] ---> Submits Rx to Specialty Hub ---> [Benefits Verification & Prior Authorization]
|
v
[Certified Specialty Pharmacy] <--- Verifies REMS Eligibility & Safe-Use --- [Patient Registered in Database]
|
v
[Direct-to-Patient/Clinic Delivery]
- Hub Enrollment: The prescription is sent to a central manufacturer-sponsored patient hub. The hub verifies that the prescribing physician is certified in the REMS database.
- Benefits Verification and PA Support: The hub case manager contacts the patient's insurer to secure prior authorization and coordinates any required copay assistance programs.
- Registry Check and Patient Education: The hub routes the prescription to a certified specialty pharmacy. The specialty pharmacy contacts the patient to complete mandatory REMS counseling and verifies that any required safe-use documentation (such as a recent negative pregnancy test or laboratory clearance) has been logged in the central database.
- Dispense Authorization: The specialty pharmacy runs a pre-dispense check against the REMS database to secure an active dispense authorization number.
- Specialized Delivery: The drug is shipped directly to the patient's home or, if it is a clinic-administered product (like a chemotherapy or a long-acting injectable), directly to the certified administering healthcare facility.
Regulatory Recalls and Enforcement Actions Linked to REMS Violations
Failure to adhere to REMS protocols is not just an administrative failure; it can result in significant regulatory enforcement actions. The FDA tracks compliance closely, and non-compliance can trigger Class II or Class III product recalls, warning letters, or clinical hold orders.
Warning Letters and Audit Failures
If a manufacturer fails to audit its certified pharmacies or neglects to report non-compliance (such as a pharmacy dispensing a drug without verifying pregnancy status), the FDA can issue a Warning Letter. These letters demand immediate corrective action plans and can lead to:
- Suspension of drug distribution.
- Civil monetary penalties.
- Rejection of supplemental NDAs/BLAs for new indications.
REMS-Related Class II Recalls
In instances where a drug is distributed outside the restricted REMS channel due to a packaging, labeling, or database integration error, the FDA may issue a recall:
- Scope: A Class II recall is initiated if the exposure to the product could cause temporary or medically reversible adverse health consequences.
- Example: If a batch of an ETASU drug is shipped to non-certified pharmacies due to a wholesale distributor database error, the manufacturer must immediately recall all units from those retail channels to prevent unauthorized dispensing.
Pre-Launch REMS Checklist for Brand and Generic Teams
Brand Launch Planning (NDA/BLA)
- Define the Risk Profile: Determine if the drug's safety risks require an ETASU or if a standard Medication Guide is sufficient.
- Design the Portal Architecture: Build a user-friendly online portal for provider training and pharmacy enrollment to minimize launch-phase friction.
- Plan the Specialty Distribution Network: Identify and contract with certified specialty pharmacies capable of managing the required pre-dispense checks.
- Coordinate with Patient Hubs: Ensure the patient support hub is fully integrated with the REMS database to prevent delays in dispense authorizations.
Generic Development Planning (ANDA)
- Identify RLD REMS Restrictions: Check the FDA REMS database to determine if the reference drug is subject to an active ETASU program.
- Initiate SSRS Outreach: Contact the brand manufacturer early in the development lifecycle to initiate Single Shared REMS negotiations.
- Document Negotiation Milestones: Keep a detailed log of all communication, meeting minutes, and draft proposals during SSRS negotiations.
- Submit Waiver Requests: If negotiations stall or if the brand refuses to negotiate in good faith for more than 12 months, compile the documentation and submit a formal waiver request to the FDA.
Frequently Asked Questions (FAQs)
What is the difference between a REMS communication plan and an ETASU program?
A communication plan is an educational tool consisting of FDA-approved letters, slide decks, and websites designed to inform providers about drug risks. An ETASU (Elements to Assure Safe Use) program consists of mandatory administrative and logistical restrictions (e.g., prescriber certification, pharmacy audits, patient registries) that must be met before the drug can be prescribed or dispensed.
Why did the FDA terminate the Clozapine REMS program in February 2025?
The FDA terminated the Clozapine REMS program because the administrative burden of the registry and database-locking requirements was causing severe clinical disruptions, including patient treatment interruptions during database transitions. The FDA determined that clozapine's benefits could be safely managed through standard clinical monitoring and Boxed Warnings without a mandatory registry database.
What is a Single Shared REMS (SSRS)?
A Single Shared REMS is a unified safety program negotiated between the brand manufacturer of a drug and generic or biosimilar entrants. It allows prescribers, pharmacies, and patients to use a single portal and registry for both the brand and generic versions of the drug, sharing the administrative costs among the manufacturers.
How does a generic manufacturer secure an FDA REMS waiver?
If a generic manufacturer is unable to reach an agreement with the brand firm on a Single Shared REMS program after good-faith negotiations (typically lasting 12 months or more), they can petition the FDA for a waiver. If approved, the generic manufacturer is allowed to launch their product with an independent REMS program that utilizes the same safety criteria but operates on separate systems.
How many active REMS programs exist, and what share require ETASU?
The FDA REMS Public Dashboard listed roughly 70 active REMS programs as of mid-2025, down from a historical high of more than 300 approved since 2008. Over 90% of the remaining active programs contain Elements to Assure Safe Use (ETASU), reflecting the agency's pattern of retiring lower-burden programs (such as stand-alone Medication Guides) and keeping REMS only where restrictive administrative controls are genuinely needed to manage serious risk.
Sources
- U.S. Food and Drug Administration (FDA). "Risk Evaluation and Mitigation Strategies (REMS)." CDER Portal. Available at https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.
- U.S. Food and Drug Administration (FDA). "REMS@FDA Database." CDER AccessData Registry. Available at https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm.
- U.S. Food and Drug Administration (FDA). "FDA Clozapine REMS Program Updates and Termination Safety Announcement (February 24, 2025)." Available at https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/clozapine-rems.
- Food and Drug Administration Amendments Act (FDAAA) of 2007, Pub. L. No. 110-85, Title IX, § 901 (adding Section 505-1 to the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355-1). Available at https://www.congress.gov/110/plaws/publ85/PLAW-110publ85.pdf.
- Janssen Pharmaceuticals Inc. "SPRAVATO (esketamine) nasal spray REMS Program Guide and Prescribing Information." Available at https://www.spravatorems.com.
- Celgene Corporation. "THALOMID (thalidomide) REMS Program Guide and Education Materials." Available at https://www.thalomidrems.com.
- U.S. House of Representatives. "21 U.S.C. 355-1 - Risk evaluation and mitigation strategies." Office of the Law Revision Counsel. Available at https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355-1&num=0&edition=prelim.
- U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG). "REMS Oversight and Implementation Analysis." Available at https://oig.hhs.gov.
